DBV Technologies DBVT DBVTF announced that its Phase 3 EPITOPE trial of epicutaneous immunotherapy (EPIT) with Viaskin Peanut in children 1 – 3 years was published in the New England Journal of Medicine.
As stated in an accompanying editorial piece, these data are seen as "very good news" for toddlers with peanut allergy, as there are currently no approved treatment options for peanut-allergic children under the age of 4 years, the journal noted.
After one year of treatment, Viaskin Peanut resulted in statistically superior desensitization compared with placebo, with treatment responder rates of 67.0% and 33.5%, respectively.
Related: DBV Technologies Outlines Regulatory Path For Viaskin Peanut Allergy Patch For Kids Below 3 Years.
Additionally, a shift towards less severe food challenge reactions was seen following 12 months of treatment with Viaskin Peanut.
Similar to previous studies of Viaskin Peanut in children, the most common adverse events were local application site reactions, which decreased in frequency and severity over time.
Low rates of treatment-related anaphylaxis and epinephrine use were observed.
The study demonstrated that 12 months of daily EPIT with a patch containing 250 µg peanut protein (1/1000th of one peanut) resulted in greater desensitization than placebo, sufficient to decrease the likelihood of experiencing an allergic reaction following accidental peanut exposure.
Price Action: DBVT shares are up 6.61% at $1.76 on the last check Thursday.
Photo by ivabalk via Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
